New research suggests that individuals who stop using new slimming jabs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who stop conventional diet and exercise programs.
Findings released in a leading medical journal points out that while obese individuals frequently drop about a fifth of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing these drugs need to be informed of the danger of quick rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to original mass in about a year and a half.
Weighing Treatments
The study, which reviewed 37 of trials involving thousands of patients, contrasted the results of GLP-1 agonists with other pills.
The team note that people who lose weight through lifestyle changes alone typically have a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Explaining the Quick Rebound
Experts propose the mode of action of the drugs is key to understanding the heightened weight return.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone levels far above than normal might result in the body to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating a significant risk."
A Chronic Issue?
Health authorities advise the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians contend that, considering the significant potential of weight regain, the therapy should be considered long-term.
This opinion is echoed by drug manufacturers, who state that the results "emphasize the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Accounts
People who have stopped the jabs describe a sudden return of appetite.
"It was like a switch flipping and I was suddenly extremely hungry," recalled an individual.
This challenge is compounded if users have not developed permanent lifestyle or habit changes during therapy.
Significant Adoption
Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, experts stress that while the jabs are potent agents for weight loss, they are not a magic solution and lasting health benefits hinges on combined behavioural management.
